EMA New Human MedicinesOriginal article
Human medicines European public assessment report (EPAR): KemSu, sufentanil,ketamine, Status: Opinion under re-examination
RegulatoryKemSuNeutral
AI Analysis
Summary
KemSu (sufentanil/ketamine) is undergoing re-examination of its opinion in the European public assessment report process, indicating an ongoing regulatory review by the EMA.
Outcome Details
Opinion under re-examination
Importance:5/10
Sentiment:
0.00
EMAEPARRegulatoryRe-examination
Read the original article
Published by EMA New Human Medicines on August 13, 2026 2:09 PM